SLDB — Solid Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- $691.69m
- $503.84m
Annual cashflow statement for Solid Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -72.2 | -86 | -96 | -125 | -174 |
| Depreciation | |||||
| Non-Cash Items | 14.5 | -10.7 | 5.59 | 19.4 | 23.2 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -23 | -3.69 | -6.34 | 2.85 | -6.82 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -77.8 | -98 | -94.2 | -100 | -156 |
| Capital Expenditures | -1.28 | -3.02 | -1.51 | -0.654 | -1.15 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -89.8 | 62.2 | 11.2 | -15.4 | -57.3 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -91.1 | 59.2 | 9.69 | -16.1 | -58.5 |
| Financing Cash Flow Items | 0.066 | 2.28 | 0.148 | -4.77 | -1.26 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 135 | 74.8 | 3.12 | 122 | 194 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -33.9 | 36 | -81.4 | 6.34 | -20.3 |